A translationally optimized AAV-UGT1A1 vector drives safe and long-lasting correction of Crigler-Najjar syndrome
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Crigler-Najjar syndrome is a severe metabolic disease of the liver due to a reduced activity of the UDP Glucuronosyltransferase 1A1 (UGT1A1) enzyme. In an effort to translate to the clinic an adeno-associated virus vector mediated liver gene transfer approach to treat Crigler-Najjar syndrome, we developed and optimized a vector expressing the UGT1A1 transgene. For this purpose, we designed and tested in vitro and in vivo multiple codon-optimized UGT1A1 transgene cDNAs. We also optimized noncoding sequences in the transgene expression cassette. Our results indicate that transgene codon-optimization is a strategy that can improve efficacy of gene transfer but needs to be carefully tested in vitro and in vivo . Additionally, while inclusion of introns can enhance gene expression, optimization of these introns, and in particular removal of cryptic ATGs and splice sites, is an important maneuver to enhance safety and efficacy of gene transfer. Finally, using a translationally optimized adeno-associated virus vector expressing the UGT1A1 transgene, we demonstrated rescue of the phenotype of Crigler-Najjar syndrome in two animal models of the disease, Gunn rats and Ugt1a1 -/- mice. We also showed long-term (>1 year) correction of the disease in Gunn rats. These results support further translation of the approach to humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sharp, P. M., & Li, W.-H. (1987) · Nucleic Acids Research · doi:10.1093/nar/15.3.1281 · Cited by 3,992
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationAdenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Self-citationLong-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273
Self-citationImmune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
Self-citationTherapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893
Self-citationCd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748
Self-citationIn vivo genome editing restores haemostasis in a mouse model of haemophilia
Li, H., Haurigot, V., Doyon, Y., Li, T., Wong, S. Y., Bhagwat, A. S., Malani, N., Anguela, X. M., Sharma, R., Ivanciu, L., et al. (2011) · Nature · doi:10.1038/nature10177 · Cited by 548
Selection and evaluation of clinically relevant AAV variants in a xenograft liver model
Lisowski, L., Dane, A. P., Chu, K., Zhang, Y., Cunningham, S. C., Wilson, E. M., Nygaard, S., Grompe, M., Alexander, I. E., & Kay, M. A. (2014) · Nature · doi:10.1038/nature12875 · Cited by 450
In Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy Vector
Zinn, E., Pacouret, S., Khaychuk, V., Turunen, H. T., Carvalho, L. S., Andres-Mateos, E., Shah, S., Shelke, R., Maurer, A. C., Plovie, E., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.07.019 · Cited by 310
Isolated Hepatocyte Transplantation in an Infant With a Severe Urea Cycle Disorder
Horslen, S. P., McCowan, T. C., Goertzen, T. C., Warkentin, P. I., Cai, H. B., Strom, S. C., & Fox, I. J. (2003) · Pediatrics · doi:10.1542/peds.111.6.1262 · Cited by 295
Wu, Z., Sun, J., Zhang, T., Yin, C., Yin, F., Van Dyke, T., Samulski, R. J., & Monahan, P. E. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300355 · Cited by 153
Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid
Vercauteren, K., Hoffman, B. E., Zolotukhin, I., Keeler, G. D., Xiao, J. W., Basner-Tschakarjan, E., High, K. A., Ertl, H. C., Rice, C. M., Srivastava, A., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.61 · Cited by 114
Cellular immune response to cryptic epitopes during therapeutic gene transfer
Li, C., Goudy, K., Hirsch, M., Asokan, A., Fan, Y., Alexander, J., Sun, J., Monahan, P., Seiber, D., Sidney, J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902269106 · Cited by 79
Research works printed but not linked: 50
- Crigler, 1952, Congenital familial nonhemolytic jaundice with kernicterus, Pediatr, 10, 169
- van der Veere, 1996, Current therapy for Crigler-Najjar syndrome type 1: report of a world registry, Hepatol, 24, 311, 10.1002/hep.510240205 · DOI · Paper page
- Chowdhury, 2001, Hereditary jaundice and disorders of bilirubin metabolism, vol. 2, 3063
- Erlinger, 2014, Inherited disorders of bilirubin transport and conjugation: new insights into molecular mechanisms and consequences, Gastroenterol, 146, 1625, 10.1053/j.gastro.2014.03.047 · DOI · Paper page
- Bosma, 2003, Inherited disorders of bilirubin metabolism, J Hepatol, 38, 107, 10.1016/S0168-8278(02)00359-8 · DOI · Paper page
- Kadakol, 2000, Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype, Hum Mutat, 16, 297, 10.1002/1098-1004(200010)16:4<297::AID-HUMU2>3.0.CO;2-Z · DOI · Paper page
- Skierka, 2013, UGT1A1 genetic analysis as a diagnostic aid for individuals with unconjugated hyperbilirubinemia, J Pediatr, 162, 1146, 10.1016/j.jpeds.2012.11.042 · doi:10.1016/j.jpeds.2012.11.042
- Labrune, 1992, Cerebellar symptoms as the presenting manifestations of bilirubin encephalopathy in children with Crigler-Najjar type I disease, Pediatr, 89, 768, 10.1542/peds.89.4.768 · doi:10.1542/peds.89.4.768
- Ostrow, 1971, Photocatabolism of labeled bilirubin in the congenitally jaundiced (Gunn) rat, J Clin Invest, 50, 707, 10.1172/JCI106541 · doi:10.1172/jci106541
- Strauss, 2006, Management of hyperbilirubinemia and prevention of kernicterus in 20 patients with Crigler-Najjar disease, Eur J Pediatr, 165, 306, 10.1007/s00431-005-0055-2 · DOI
- Sellier, 2012, Successful plasmapheresis for acute and severe unconjugated hyperbilirubinemia in a child with crigler najjar type I syndrome, JIMD Rep, 2, 33, 10.1007/8904_2011_40 · DOI
- Kaneko, 2000, Bilirubin adsorption therapy and subsequent liver transplantation cured severe bilirubin encephalopathy in a long-term survival patient with Crigler-Najjar disease type I, Intern Med, 39, 961, 10.2169/internalmedicine.39.961 · doi:10.2169/internalmedicine.39.961
- Adam, 2012, Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR), J Hepatol, 57, 675, 10.1016/j.jhep.2012.04.015 · DOI · Paper page
- Immordino, 2014, Predictability and survival in liver replantransplantation: monocentric experience, Transplantation proceedings, 46, 2290, 10.1016/j.transproceed.2014.07.039 · doi:10.1016/j.transproceed.2014.07.039
- Pedersen, 2014, Infections after orthotopic liver transplantation, J Clin Exp Hepatol, 4, 347, 10.1016/j.jceh.2014.07.004 · DOI
- Buchlis, 2012, Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer, Blood, 119, 3038, 10.1182/blood-2011-09-382317 · DOI · Paper page
- Seppen, 2006, Adeno-associated virus vector serotypes mediate sustained correction of bilirubin UDP glucuronosyltransferase deficiency in rats, Mol Ther, 13, 1085, 10.1016/j.ymthe.2006.01.014 · DOI · Paper page
- Pastore, 2012, Sustained reduction of hyperbilirubinemia in Gunn rats after adeno-associated virus-mediated gene transfer of bilirubin UDP-glucuronosyltransferase isozyme 1A1 to skeletal muscle, Hum Gene Ther, 23, 1082, 10.1089/hum.2012.018 · DOI
- Bortolussi, 2012, Rescue of bilirubin-induced neonatal lethality in a mouse model of Crigler-Najjar syndrome type I by AAV9-mediated gene transfer, FASEB J, 26, 1052, 10.1096/fj.11-195461 · DOI
- Bortolussi, 2014, Life-long correction of hyperbilirubinemia with a neonatal liver-specific AAV-mediated gene transfer in a lethal mouse model of Crigler-Najjar Syndrome, Hum Gene Ther, 25, 844, 10.1089/hum.2013.233 · DOI · Paper page
- Junge, 2015, Adeno-associated virus vector-based gene therapy for monogenetic metabolic diseases of the liver, J Pediatr Gastroenterol Nutr, 60, 433, 10.1097/MPG.0000000000000703 · DOI
- Fagiuoli, 2013, Monogenic diseases that can be cured by liver transplantation, J Hepatol, 59, 595, 10.1016/j.jhep.2013.04.004 · DOI · Paper page
- Fox, 1998, Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation, N Engl J Med, 338, 1422, 10.1056/NEJM199805143382004 · DOI · Paper page
- Sneitz, 2010, Crigler-Najjar syndrome in The Netherlands: identification of four novel UGT1A1 alleles, genotype-phenotype correlation, and functional analysis of 10 missense mutants, Hum Mutat, 31, 52, 10.1002/humu.21133 · doi:10.1002/humu.21133
- Iyanagi, 1991, Molecular basis of multiple UDP-glucuronosyltransferase isoenzyme deficiencies in the hyperbilirubinemic rat (Gunn rat), J Biol Chem, 266, 24048, 10.1016/S0021-9258(18)54390-8 · DOI
- Nathwani, 2006, Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver, Blood, 107, 2653, 10.1182/blood-2005-10-4035 · DOI · Paper page
- Snyder, 1997, Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice, Hum Gene Ther, 8, 1891, 10.1089/hum.1997.8.16-1891 · DOI · Paper page
- Miao, 2000, Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro, Mol Ther, 1, 522, 10.1006/mthe.2000.0075 · DOI · Paper page
- Bortolussi, 2014, Age-dependent pattern of cerebellar susceptibility to bilirubin neurotoxicity in vivo in mice, Dis Model Mech, 7, 1057, 10.1242/dmm.016535 · DOI
- Ambrosino, 2005, Isolated hepatocyte transplantation for Crigler-Najjar syndrome type 1, Cell Transplant, 14, 151, 10.3727/000000005783983250 · DOI · Paper page
- Dobbelaere, 2014, Phase I/II multicenter trial of liver derived mesenchymal stem cells (HepastemR) for the treatment of urea cycle disorder and Crigler Najjar syndrome interim analysis at 6 months post infusion, J Inherited Metab Dis, 37, O-027
- Dimmock, 2011, Correction of hyperbilirubinemia in gunn rats using clinically relevant low doses of helper-dependent adenoviral vectors, Hum Gene Ther, 22, 483, 10.1089/hum.2010.167 · doi:10.1089/hum.2010.167
- Schmitt, 2010, Lentiviral vectors that express UGT1A1 in liver and contain miR-142 target sequences normalize hyperbilirubinemia in Gunn rats, Gastroenterol, 139, 999, 10.1053/j.gastro.2010.05.008 · DOI · Paper page
- Binny, 2012, AAV-mediated gene transfer in the perinatal period results in expression of FVII at levels that protect against fatal spontaneous hemorrhage, Blood, 119, 957, 10.1182/blood-2011-09-377630 · DOI · Paper page
- Zhou, 2015, Nonoptimal codon usage influences protein structure in intrinsically disordered regions, Mol Microbiol, 97, 974, 10.1111/mmi.13079 · DOI · Paper page
- Powell, 2015, Viral expression cassette elements to enhance transgene target specificity and expression in gene therapy, Discov Med, 19, 49
- Bullock, 1996, Ribosomal scanning past the primary initiation codon as a mechanism for expression of CTL epitopes encoded in alternative reading frames, J Exp Med, 184, 1319, 10.1084/jem.184.4.1319 · DOI · Paper page
- Ehrhardt, 2003, Episomal persistence of recombinant adenoviral vector genomes during the cell cycle in vivo, J Virol, 77, 7689, 10.1128/JVI.77.13.7689-7695.2003 · DOI · Paper page
- Wang, 2012, Hepatic gene transfer in neonatal mice by adeno-associated virus serotype 8 vector, Hum Gene Ther, 23, 533, 10.1089/hum.2011.183 · DOI · Paper page
- Coppoletta, 1933, Body length and organ weights of infants and children: a study of the body length and normal weights of the more important vital organs of the body between birth and twelve years of age, Am J Pathol, 9, 55
- Nathwani, 2007, Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates, Blood, 109, 1414, 10.1182/blood-2006-03-010181 · DOI · Paper page
- Meliani, 2016, Antigen-specific modulation of capsid immunogenicity with tolerogenic nanoparticles results in successful AAV vector readministration, Mol Ther, 24, S34, 10.1016/S1525-0016(16)32886-6 · DOI
- Anguela, 2013, Robust ZFN-mediated genome editing in adult hemophilic mice, Blood, 122, 3283, 10.1182/blood-2013-04-497354 · DOI · Paper page
- Barzel, 2015, Promoterless gene targeting without nucleases ameliorates haemophilia B in mice, Nature, 517, 360, 10.1038/nature13864 · DOI · Paper page
- Thummel, 1982, Construction of adenovirus expression vectors by site-directed in vivo recombination, J Mol Appl Genet, 1, 435
- Ayuso, 2010, High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency, Gene Ther, 17, 503, 10.1038/gt.2009.157 · DOI · Paper page
- Matsushita, 1998, Adeno-associated virus vectors can be efficiently produced without helper virus, Gene Ther, 5, 938, 10.1038/sj.gt.3300680 · DOI · Paper page
- Ying, 2007, Substitution of the use of radioactivity by fluorescence for biochemical studies of RNA, RNA, 13, 2042, 10.1261/rna.637907 · DOI
- Cornelius, 1972, Animal model of human disease. Crigler-Najjar Syndrome. Animal model: hereditary nonhemolytic unconjugated hyperbilirubinemia in Gunn rats, Am J Pathol, 69, 369
- Montenegro-Miranda, 2013, Adeno-associated viral vector serotype 5 poorly transduces liver in rat models, PLoS One, 8, e82597, 10.1371/journal.pone.0082597 · DOI
Cited by
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Emerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
Self-citationAAV vectors: The Rubik’s cube of human gene therapy
Pupo, A., Fernández, A., Low, S. H., François, A., Suárez-Amarán, L., & Samulski, R. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.015 · Cited by 360
Meliani, A., Boisgerault, F., Hardet, R., Marmier, S., Collaud, F., Ronzitti, G., Leborgne, C., Costa Verdera, H., Simon Sola, M., Charles, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06621-3 · Cited by 265
Self-citationUnraveling the complex story of immune responses to AAV vectors trial after trial.
Vandamme, C., Adjali, O., & Mingozzi, F. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.150 · Cited by 234
Self-citation
Metadata
- Authors
- Ronzitti, G., Bortolussi, G., van Dijk, R., Collaud, F., Charles, S., Leborgne, C., Vidal, P., Martin, S., Gjata, B., Sola, M. S., van Wittenberghe, L., Vignaud, A., Veron, P., Bosma, P. J., Muro, A. F., & Mingozzi, F.
- Venue
- Molecular Therapy - Methods & Clinical Development
- Publisher
- Elsevier BV
- Published
- 2016
- Volume
- 3
- Pages
- 16049
- ISSN
- 2329-0501 (ISSN-L)
- OpenAlex
- W2475768353
- Cited by
- 69
- References
- 14
- FWCI
- 6.85
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 414 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.